Main outcomes work/ programme(s)
Milestone contribution to heart failure (HF) therapy, through leadership of major clinical trials, mainly with mineralocoticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF, NEJM and ALBATROSS, REMINDER, ARTS-HF EHJ), but also with beta-blockers (CIBIS Lancet, CAPRICORN Lancet), Angio2 receptor blockers (VALIANT, HEAAL, NEJM), Direct Renin Inhibitors (ASTRONAUT, JAMA), and vasopressin antagonists (EVEREST, JAMA), Sacubutril/valsartan (PARAGON, NEJM), SGLT2 inhibitors (EMPEROR-Reduced and EMPEROR-Preserved, NEJM, The Lancet) which have led to the approval of new drugs in this area and/or change in international guidelines.